With the help of our TranscriptomeArchitect platform, there are now thousands of experimentally validated Antisense OligoNucleotides targeting hundreds of genes. More than 2 million Antisense OligoNucleotides modulating transcript degradation and exon splicing have been designed for the entire human transcriptome. This rich resource is now stored in the TranscriptomeViewer, enabling scientists to access more than 2 millions oligos to quickly and efficiently advance their research.
The TranscriptomeViewer is a scientific visualizer that allows researchers to examine specific transcripts or exon targets, and understand the possible effects of their splicing modulation. This tool is developed at the Agency of Science Technology and Research, Singapore (A*STAR) and is freely available for the research community to use. More than 2 millions NOA-Switch™ and NOA-NMD™ designed by our TranscriptomeArchitect are now available in the viewer to enable scientists to have easy access to these oligos. With the viewer, researchers can examine how specific splice modulation can affect the functional protein domains for coding transcripts and create experimentally testable hypotheses on the cell phenotypes.
The AONs are supplied in lyophilized powder or gel form and can be re-suspended in distilled, sterile water or PBS buffer. They are very soluble in water.
The AONs must be stored at ≤-20 ºC. When stored in powder form, the AONs are very stable for more than 1 year. Once re-suspended in water or buffer, it is recommended to aliquot them and use within 1 year. It is recommended to prepare small aliquots in order to avoid repeated freeze-thaw cycles.
In order for the 2-O-Methyl phosphorothioate AONs to be functional in the alteration of a specific splicing event, they must be able to access the nucleus of the cell, where the splicing reaction takes place. The AONs synthesized with this chemistry are capable to self-penetrate the cell (and the nucleus) when added to the media in multiple cell types. However, we recommend using transfection reagents or electroporation that will allow to achieve the desired splicing switch with a minimal amount of AONs in in vitro experiments. A titration of the AON concentration is highly recommended for all the experiments performed.
Naked AONs are simply added to culture medium once re-suspended in water or PBS buffer. It must be taken in consideration that the naked AON uptake is cell-type specific: cells with “endocytic nature” (e.g. APCs) will be able to naturally have more productive switching, while secretory cells (e.g. T cells) are going to be less prone to internalize the AONs. Usually, the amount of AON tolerated by cells in the medium spans in the range of single-digit µM to nM.
We noticed that the transfection reagents and protocols used for siRNA or plasmid’s transfection are working for AON as well, leading to an improved uptake of AON in cultured cells. We noticed a sensibly better performance for AON’s transfection in adherent cells, such as lung carcinoma A549, and prostate cancer cell lines PC-3 and LnCap, using RNAiMAX and Lipofectamine 3000 compared to Lipofectamine 2000 (see Protocols section). With Lipofectamine 3000 as transfection reagent, the IC50 of an effective AONs can range from 5 nM to 250 nM depending on the cell lines and target genes.
For cells cultured in suspension, electroporation systems have been shown to suit the AON intra-nuclear delivery maintaining the same parameters used for siRNA and plasmids.
Our previous study (Lin J et al., 2017) with mouse xenograph models showed that intraperitoneal injection of the naked AONs has successfully induced target exon skipping and inhibited tumor growth.
Splicing is a constant and dynamic process. The switches in the desired splicing event can be observed as early as within a few hours from the transfection of the AON. The factors influencing the kinetic and efficacy of the switch are multiple: transcript abundance, transcription turnover, stability, etc. The switch can last for numerous days, depending on the target transcript, cell type, and replication rate.
If the AON is not meant to induce the degradation of the target transcript, the detection of the splicing switch is usually straightforward. A simple RT-PCR with primers designed on the flanking exons will be sufficient to visualize on an agarose gel the two different bands (full length isoform and “skipped” isoform). This method allows a rapid and clear quantification of the AON efficiency. A TaqMan PCR, specific for the two isoforms, can be designed for improved quantification sensitivity and reproducibility (Dewaele M et al., 2016).
However, it might happen that the target exon doesn’t have flanking exons that are constitutively included in the transcript. We suggest to carefully look at the alternative splicing occurring in the surroundings of the desired splicing modulation. In case the alternative splicing pattern is particularly complex, we suggest to design the primers on constitutive exons and use capillary electrophoresis to detect and quantify all the possible isoforms (Tabaglio T et al.).
For AONs designed to induce degradation through nonsense-mediated decay (NMD), the switch will not be easily quantifiable since the isoform subject to NMD will be degraded. A simple quantitative PCR (qPCR) to detect the decrease of the target mRNA in this case will suffice to assess the efficacy of the AON switch. In combination, a treatment of the cells for few hours with cycloheximide before cell harvest will block the NMD process, allowing a more reliable quantification of the switch.
Possible reasons and solutions:
Using this protocol, we have successfully transfected AONs into the following cell lines: A549, Hela, RPE, THP-1, RS4:11, SHSY5Y, SEM, LnCap, PC-3 and U87MG.
Using this protocol, we have successfully transfected AONs into LnCap and PC-3 cells with higher efficiency as compared to Lipofectamine 2000 or 3000.